Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Studie účinnosti a bezpečnosti přípravku DFL24498 při léčbě AKC

16. září 2026 aktualizováno: Dompé Farmaceutici S.p.A

A Phase 3, Multicenter, Randomized, Double-Masked, Vehicle-Controlled Study to Demonstrate Efficacy and Safety of DFL24498 Eye Drop Solution in Participants With Atopic Keratoconjunctivitis (AKC)

This is a phase 3, multicenter, randomized, double-masked, parallel-group, vehicle-controlled study to evaluate the safety and efficacy of DFL24498 compared with vehicle ophthalmic solution, in participants with AKC. The study consists of 2 cohorts: the adult cohort includes approximately 138 participants and the pediatric cohort which includes approximately 15 participants. The cohorts will be randomized separately. Adult participants will be randomized in a 1:1 ratio, while pediatric participants will be randomized in a 2:1 ratio to receive DFL24498 or vehicle.

Přehled studie

Postavení

Nábor

Podmínky

Intervence / Léčba

Detailní popis

The study will consist of 3 periods:

  1. Washout period (from Day -7 ± 1 to Day 1),
  2. Treatment Period (from randomization through Week12) and
  3. Follow-up period (Weeks 13 to 16).

Typ studie

Intervenční

Zápis (Odhadovaný)

153

Fáze

  • Fáze 3

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

  • Jméno: Dompé farmaceutici S.p.A. Via Santa Lucia, 6, 20122 Milan (MI)
  • Telefonní číslo: +39 02 583 831

Studijní místa

      • Bologna, Itálie, 40138
        • Nábor
        • IRCCS AOU di Bologna - Policlinico Sant'Orsola UO Oftalmologia
      • Chieti, Itálie, 66100
        • Nábor
        • Ospedale SS Annunziata, ASL 2 Lanciano Vasto Chieti
      • Florence, Itálie, 50134
        • Nábor
        • Azienda Ospedaliero Universitaria Careggi
      • Roma, Itálie, 00161
        • Nábor
        • AOU Policlinico Umberto I
      • Roma, Itálie, 00128
        • Nábor
        • Fondazione Policlinico Universitario Campus Bio-Medico
      • Verona, Itálie, 37134
        • Nábor
        • Azienda Ospedaliera Universitaria Integrata Verona
    • Florida
      • Jacksonville, Florida, Spojené státy, 32256
        • Nábor
        • Bowden Eye Associates - Southside Location
      • Miami, Florida, Spojené státy, 33136
        • Nábor
        • University of Miami, Miller School of Medicine, Bascom Palmer Eye Institute
    • Georgia
      • Morrow, Georgia, Spojené státy, 30260
        • Nábor
        • Clayton Eye Clinical Research
    • Missouri
      • St Louis, Missouri, Spojené státy, 63131
        • Nábor
        • Ophthalmology Associates
    • New York
      • New York, New York, Spojené státy, 10017
        • Nábor
        • NYU Langone Health - Eye Center
    • North Carolina
      • Durham, North Carolina, Spojené státy, 27710
        • Nábor
        • Duke Eye Center - Ophthalmology
    • Tennessee
      • Memphis, Tennessee, Spojené státy, 38119
        • Nábor
        • Total Eye Care, PA
    • Texas
      • Houston, Texas, Spojené státy, 77030
        • Nábor
        • Baylor University Jamail Specialty Care Center- Alkek Eye Center- Ophthalmology
      • Córdoba, Španělsko, 14012
        • Nábor
        • METAVISION ARRUZAFA S.L. (Hospital Arruzafa)
      • Santiago de Compostela, Španělsko, 15706
        • Nábor
        • Miranza Galicia
      • Valencia, Španělsko, 46015
        • Nábor
        • Fundación de Oftalmología Médica de la Comunitat Valenciana (FOM)
      • Valladolid, Španělsko, 47011
        • Nábor
        • OBA - Universidad de Valladolid
      • Zaragoza, Španělsko, 50009
        • Nábor
        • Hospital Universitario Miguel Servet

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

10 let až 65 let (Dítě, Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

Participants are eligible to be included in the study only if all of the following criteria apply:

  1. Male or Female aged ≥ 10 and ≤ 65 years.

  2. Diagnosis of AKC in both eyes, including the presence or medical history of the following:

    1. other atopic condition (ie., atopic dermatitis, periocular eczema, asthma, allergic rhinitis), AND
    2. chronic allergic blepharoconjunctivitis and/or keratoconjunctivitis.
  3. Ocular itching of at least 50 as assessed by VAS scale.

  4. Corneal fluorescein staining assessed by modified Oxford scale of at least grade 1 AND a bulbar conjunctival hyperemia assessed by VBR 10 scale of at least 40 (range 0 to 100) in the same eye.

  5. A composite symptoms score (CSyS) ≥ 5 (sum of the severity scores graded 0 to 3 for each of the following: itching, tearing, ocular discomfort, photophobia, and mucous discharge score) (CSyS range of 0 to 15).

  6. If a woman of childbearing potential (WOCBP), must have a negative pregnancy test at both screening and baseline visit, and use an acceptable contraception method.

Exclusion Criteria:

Participants will be excluded if any of the following criteria apply:

  1. Inability to speak and understand the local language sufficiently to understand the nature of the study, to provide written informed consent, and to allow the completion of all study assessments.
  2. Evidence of an active ocular infection in either eye.
  3. Intraocular inflammation defined as anterior chamber flare > 0 by Standardization of Uveitis Nomenclature (SUN) grading, in either eye.
  4. Known or suspected ocular malignancy (ocular surface, intraocular, ocular adnexa).
  5. Presence of cancer or any other systemic or unstable disease that may affect the ability to participate in the clinical study in the opinion of the investigator including basal cell carcinoma.
  6. Participants that are anatomically monocular.
  7. Systemic disease not stabilized within 1 month before the screening visit (eg, diabetes with glycemia out of range, thyroid malfunction) or judged by the investigator to be incompatible with the study (eg, current systemic infections) or with a condition incompatible with the frequent assessment required by the study.

Note: Additional protocol defined Inclusion/Exclusion criteria apply

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Trojnásobný

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: DFL24498

Participants will be administered with DFL24498 eye drops in both eyes.

DFL24498 will be instilled in each eye for 12 Weeks.

Rescue medication may be administered as required at the Investigator discretion.

Komparátor placeba: Vehicle

Participants will be administered with vehicle eye drops in both eyes.

Rescue medication may be administered as required at the Investigator discretion.

Vehicle eye drops without active drug will be instilled in each eye for 12 Weeks.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Change from baseline at week 6 in ocular itching score assessed by visual analog scale (VAS).
Časové okno: Baseline and at Week 6

The ocular itching VAS ranges from 0 to 100 mm (0 mm = no ocular itching at all, 100 mm = intolerable itching). Participants will be asked to subjectively rate the current severity of ocular itching at each time point.

Baseline and at Week 6

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Change from baseline at week 6 in corneal epithelial fluorescein staining, scored by modified Oxford scale, in the study eye.
Časové okno: Baseline and at Week 6

Fluorescein will be applied to the inferior fornix of the palpebral conjunctiva of each eye. To avoid the phenomenon of quenching, staining will be assessed within 1 to 4 minutes from fluorescein instillation. Examination will be performed at the slit-lamp using blue (cobalt) light. Corneal fluorescein staining will be graded according to the modified Oxford scale (7-point scale: 0, 0.5. 1, 2, 3, 4, 5).

Baseline and at Week 6
Change from baseline at week 6 in bulbar conjunctival hyperemia assessed by Validated Bulbar Redness (VBR) 10 scale (0 to 100), in the study eye.
Časové okno: Baseline and at Week 6

Bulbar conjunctival redness will be assessed at the slit-lamp examination using white light prior to vital dye instillation and graded according to the VBR 10 scale.

Baseline and at Week 6
Change from baseline over time in ocular itching score assessed by VAS.
Časové okno: Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16

The ocular itching VAS ranges from 0 to 100 mm (0 mm = no ocular itching at all, 100 mm = intolerable itching). Participants will be asked to subjectively rate the current severity of ocular itching at each time point.

Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16
Change from baseline over time in ocular symptoms of itching, tearing, discomfort, mucous discharge, and photophobia on a 4-point scale (0 to 3).
Časové okno: Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16

Ocular symptoms are assessed using a 4-point severity scale ranging from 0 (none) to 3 (severe). Five ocular symptoms, itching, tearing, ocular discomfort (including burning, stinging, and foreign body sensation), mucous discharge, and photophobia are evaluated in the study eye. A composite symptom score is described in calculated at screening and Baseline by summing the individual symptom scores, resulting in a total score range of 0 to 15, with higher scores indicating greater symptom severity.

Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16
Change from baseline over time in corneal fluorescein staining (modified Oxford scale) in the study eye.
Časové okno: Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16

Corneal fluorescein staining modified Oxford scale (0-5) as per corneal dot count in each eye.

Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16
Change from baseline over time in bulbar conjunctival hyperemia assessed by VBR 10 scale (0 to 100) in the study eye.
Časové okno: Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16

Bulbar conjunctival hyperemia assessed by Validated Bulbar Redness (VBR) 10 scale (0 to 100).

Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16
Change from baseline over time in signs of tarsal papillary reaction, corneal neovascularization, cicatrizing conjunctivitis and blepharitis on a 4-point scale (0 to 3) in the study eye.
Časové okno: Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16

Change in signs on a 4-point scale (0 to 3) in the study eye.

Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16
Change from baseline at week 6 and 12 in the QoL scores assessed by the Standardized Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ-S) (assessed in the adult cohort only)
Časové okno: Baseline and at Week 6 and Week 12.

Standardized Rhinoconjunctivitis QoL Questionnaire (RQLQ[S]) is a validated questionnaire that assesses QoL specifically in patients with rhinoconjunctivitis. There are 28 questions, which are categorized under 7 domains (activities, sleep, non-nose/eye symptoms, practical problems, nasal symptoms, eye symptoms, and emotional). Each question is scored on a 7-point scale from no impairment (score 0) to severe impairment (score 6).

Baseline and at Week 6 and Week 12.
Patient Global Impression of Change (PGIC) at week 6 and week 12 (assessed in the adult cohort only)
Časové okno: At week 6 and week 12.

PGIC is a short questionnaire used to assess how a participant perceives changes in their condition following treatment, on a scale ranging from 1 to 7.

At week 6 and week 12.
Number of Participants receiving rescue medication over time after week 6
Časové okno: Week 6 to Week 12

Participants who received rescued medication over time after week 6 (visit 4).

Week 6 to Week 12
Number of participants with treatment-emergent adverse events and serious adverse events (SAEs)
Časové okno: Up to Week 16

Any adverse events occurring or worsening after the first administration of investigational product is classified as "treatment-emergent" adverse events and does not necessarily have a causal relationship with the intervention. A SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product, and is medically important.

Up to Week 16
Change from baseline over time in best corrected distance visual acuity (BCDVA) in each eye.
Časové okno: Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16

Best corrected visual acuity (BCDVA) is determined by careful refraction according to the standard protocol for refraction. BCDVA is measured by Early Treatment of Diabetic Retinopathy Study chart.

Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16
Change from baseline at week 12 in corneal endothelial cell density in each eye (only at selected sites that have the required equipment).
Časové okno: Baseline and at week 12

Corneal central region endothelial cell density will be determined for each eye using specular microscopy and expressed as the number of cells/mm2 using the Cell Density readout provided by the software.

Baseline and at week 12
Change from baseline at week 12 in dilated fundus exam in each eye
Časové okno: Baseline and at week 12

After specular microscopy, mydriatic drops will be instilled in both eyes and once adequate dilation is achieved, a fundal exam shall be performed to examine the vitreous, retina, and optic nerve.

Baseline and at week 12
Change from baseline over time in intraocular pressure in each eye.
Časové okno: Baseline and at Week 6 and Week 12

IOP will be assessed by tonometry for each eye and will be measured in mmHg.

Baseline and at Week 6 and Week 12
Number of participants discontinued due to tolerability during the treatment period
Časové okno: Baseline to week 12

Treatment discontinuation rate due to tolerability.

Baseline to week 12

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

1. prosince 2025

Primární dokončení (Odhadovaný)

1. března 2027

Dokončení studie (Odhadovaný)

1. května 2027

Termíny zápisu do studia

První předloženo

22. prosince 2025

První předloženo, které splnilo kritéria kontroly kvality

3. února 2026

První zveřejněno (Aktuální)

9. února 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

21. září 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

16. září 2026

Naposledy ověřeno

1. září 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • ICY-AKC-301
  • 2025-522291-83-00 (Ctis)
  • 2025 (Grant/smlouva NIH USA)

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NE

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ano

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .